Ekso Bionics Launches GaitCoach Software for EksoNR
2024年1月9日 - 6:05AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced the launch of GaitCoach™, its next
generation gait therapy software for EksoNR.
GaitCoach is a comprehensive gait therapy
software that supports a broad spectrum of patients who use EksoNR.
This new software simplifies the use of robotics with the intention
of improving user trust in technology, providing impactful, dynamic
feedback and offering specific guidance acting as an extra set of
clinical eyes. Ekso believes GaitCoach will reduce training demands
and increase utilization, making the device more intuitive and
easier to use for both patients and physical therapists. GaitCoach
will replace SmartAssist, the software that has been in use since
2016 and was optimized in 2019 with the launch of EksoNR.
“By listening to the feedback of physical
therapists, clinicians and patients, Ekso Bionics has elevated
EksoNR with GaitCoach, a new software solution designed to further
improve patient rehabilitation,” said Scott Davis, Chief Executive
Officer of Ekso Bionics. “GaitCoach helps customize patient
sessions to be better aligned with their deficits and goals,
allowing therapists to treat patients more efficiently. We are
proud of the work and commitment of our engineering and clinical
teams, who communicated regularly with frequent users of EksoNR in
the design process.”
When introduced to GaitCoach, experienced users
of EksoNR have shared the following:
- 96% found GaitCoach software very
or extremely intuitive
- 93% feel the guidance from
GaitCoach is valuable and makes EksoNR easier to use
- 93% think EksoNR with GaitCoach
would be useful for new or less experienced therapists at their
clinic
- 93% feel the GaitCoach provided
focuses would help them achieve their clinical goals
- 79% feel GaitCoach would help them
progress their patients more easily
The software is initially available only in the
U.S. A demonstration of the software can be found on the Company’s
website at https://eksobionics.com/eksonr/.
About Ekso Bionics®Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical and industrial applications.
Founded in 2005, the Company continues to build upon its
industry-leading expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only known exoskeleton company to offer technologies that range
from helping those with paralysis to stand up and walk, to
enhancing human capabilities on job sites across the globe. The
Company is headquartered in the San Francisco Bay Area and is
listed on the Nasdaq Capital Market under the symbol “EKSO.” For
more information, visit: www.eksobionics.com or follow @EksoBionics
on X.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the potential benefits of GaitCoach, (ii)
the performance or effectiveness of the Company’s products,
including the EksoNR, and (iii) the assumptions underlying or
relating to any statement described in clauses (i) and (ii) above.
Such forward-looking statements are not meant to predict or
guarantee actual results, performance, events or circumstances and
may not be realized because they are based upon the Company’s
current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, patient or therapist dissatisfaction
with or delay or failure to adopt GaitCoach and risks related to
product liability, recall and warranty claims. These and other
factors are identified and described in more detail in the
Company’s filings with the U.S. Securities and Exchange Commission.
To learn more about Ekso Bionics please visit the Company’s website
at www.eksobionics.com or follow @EksoBionics on X. The Company
does not undertake to update these forward-looking statements.
Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
過去 株価チャート
から 8 2024 まで 9 2024
Ekso Bionics (NASDAQ:EKSO)
過去 株価チャート
から 9 2023 まで 9 2024